基于組學(xué)技術(shù)探討生物標(biāo)記物在抑郁癥中的研究進(jìn)展
摘要 基于組學(xué)技術(shù)綜述神經(jīng)遞質(zhì)、神經(jīng)內(nèi)分泌系統(tǒng)、精神神經(jīng)免疫系統(tǒng)、神經(jīng)營養(yǎng)因子系統(tǒng)、代謝及神經(jīng)影像學(xué)六大潛在抑郁癥生物學(xué)標(biāo)志物在抑郁癥診斷、治療、干預(yù)效果觀察、預(yù)后及護(hù)理中的作用,以期對后續(xù)抑郁癥的研究臨床診治及護(hù)理工作提供支持。
關(guān)鍵詞 抑郁癥;生物學(xué)標(biāo)志物;炎癥;氧化應(yīng)激;綜述
doi:10.12102/j.issn.1009-6493.2025.01.026
基金項目 2023—2024年度山西省大健康產(chǎn)業(yè)高質(zhì)量發(fā)展科研專項項目,編號:DJKZXKT2023002;山西省食療和農(nóng)產(chǎn)品處方產(chǎn)業(yè)技術(shù)創(chuàng)新戰(zhàn)略聯(lián)盟項目基金
作者簡介 劉洽,護(hù)士,碩士研究生在讀
通訊作者 韓世范,E?mail:[email protected];朱瑞芳,E?mail: [email protected]
引用信息 劉洽,程俊香,劉娜,等.基于組學(xué)技術(shù)探討生物標(biāo)記物在抑郁癥中的研究進(jìn)展[J].護(hù)理研究,2025,39(1):151?159.
Research progress on biomarkers in depression based on omics technologies
LIU Qia1, CHENG Junxiang1,2,LIU Na2,YANG Guofang1, MA Chenjing1, ZHAO Yiwen3, ZHU Ruifang1,2,3*, HAN Shifan1,2,4,5,6*
1.Nursing College, Shanxi Medical University, Shanxi 030001 China;2.First Hospital of Shanxi Medical University;3.Shanxi Medical Periodical Press Co.,Ltd.;4.Shanxi Province Food Therapy and Agricultural Products Prescription Industry Technology Innovation Strategic Alliance;5.Major Platform Carrier and Training Base for the Integration of Health Industry and Education in Shanxi Province;6.Dietotherapy Science and Technology Research Center, Shanxi Medical University
*Corresponding Author HAN Shifan, E?mail: [email protected]; ZHU Ruifang, E?mail: [email protected]
Abstract It summarizes the roles of six potential biological markers of depression based on omics technologies, including neurotransmitters, the neuroendocrine system,the psychoneuroimmune system,neurotrophic factor systems,metabolism?related factors, and neuroimaging, in the diagnosis,treatment,observation of intervention effects, and prognosis of depression. The aim is to provide support for subsequent research clinical diagnosis and treatment and nursing work on depression.
Keywords depression; biological markers; inflammation; oxidative stress; review
抑郁癥(MDD)是一種常見的精神障礙,以持續(xù)的情緒低落、興趣減退、意志力降低為主要臨床表現(xiàn),其終身患病率約為17%,全球約有3.5億人受其影響。(剩余29276字)